In this review:
NGS for determining cytogenetic risk in CASTOR and POLLUX studies
Cytogenetic risk status for DRd vs. DVd in relapsed/refractory MM
MRD in transplant-eligible new MM
Anti-BCMA chimeric antigen receptor T-cells for relapsed/refractory MM
Quadruplet vs. sequential triplet induction for transplant-eligible MM
KRd vs. KCd induction for new MM
Venetoclax, bortezomib, dexamethasone in relapsed/refractory MM
BCL2 expression for predicting venetoclax, bortezomib,dexamethasone response
Denosumab noninferior to zoledronic acid for bone disease in new MM
Pembrolizumab, lenalidomide, low-dose dexamethasone for relapsed/refractory MM
Please login below to download this issue (PDF)